Abstract: Objective To evaluate the clinical efficacy and safety of domestic Bortezomib (Xintai) based regimen in the treatment of multiple myeloma. Methods Patients with multiple myeloma who received the domestic Bortezomib (Xintai) based treatment in Beijing Chao-Yang Hospital, Capital Medical University were selected as the study subjects to analyze the clinical efficacy and adverse reactions. Results A total of 117 patients with multiple myeloma were included, 80 newly diagnosed patients and 37 relapsed/refractory patients. After 4 cycles of median therapy(range 1-11 cycles), the overall response rate (ORR) was 72.6% (85/117), 91.3% (73/80) for newly diagnosed multiple myeloma and 32.4% (12/37) for relapsed/refractory multiple myeloma. The adverse reactions were mainly in grade 1-2, among which hematologic adverse reactions were mainly leukopenia and thrombocytopenia, with the incidence of 35.0% (41/117) and 32.5% (38/117), respectively; while the non-hematological adverse reactions were mainly neuropathy (32.5%, 38/117) and gastrointestinal reactions (53.0%, 62/117), respectively. Conclusions Domestic Bortezomib (Xintai) is suitable for the first-line treatment of newly diagnosed multiple myeloma patients, with good efficacy and tolerance, but the long-term efficacy require a further follow-up; the clinical efficacy of patients with relapsed and refractory multiple myeloma is poor.

Key words: Multiple myeloma, Bortezomib, Efficacy, Adverse reaction